Katherine completed an M.Chem. degree at the University of Oxford, working under the supervision of Prof. Jeremy Robertson for her final year research project. In 2002, she joined the Medicinal Chemistry department at Pfizer in Sandwich, UK, where she worked in drug discovery across a variety of disease areas and drug classes. Katherine joined the Structural Genomics Consortium at the University of Oxford in 2011, where she designed and synthesized inhibitors of epigenetic proteins and was awarded a D.Phil. in Organic Chemistry under the supervision of Prof. Christopher Schofield and Prof. Paul Brennan.
In 2015, she joined the newly formed Alzheimer’s Research UK Oxford Drug Discovery Institute, where she is part of a multi-disciplinary research team working on target identification and drug discovery for dementia.
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
O’Brien DP. et al, (2022)
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
Rusilowicz-Jones EV. et al, (2020), Life Science Alliance, 3, e202000768 - e202000768
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Le Bihan Y-V. et al, (2019), European journal of medicinal chemistry, 177, 316 - 337
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Tumber A. et al, (2017), Cell Chemical Biology, 24, 371 - 380
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
Jones P. et al, (2017), Journal of Medicinal Chemistry, 60, 767 - 786